Close Menu
April 08, 2021
Sponsored by

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

Genome Webinar

Senior Scientist
Medical University of Graz

Genomics is central to the precision oncology cascade. After tissue or blood is subjected to next-generation sequencing (NGS) and bioinformatics analysis, the alterations detected must be annotated and interpreted within the context of the individual patient.

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

Samantha Hasenleithner of the Medical University of Graz will discuss the approach, which reflects a true clinical scenario in which both plasma and tissue analytes help inform treatment decisions. Nevertheless, this workflow poses challenges for clinicians in selecting the appropriate treatment.

Clinical decision support may help streamline these variant interpretation and treatment matching workflows, and Dr. Hasenleithner will discuss an evaluation of three such tools and her team’s experience with the Navify Mutation Profiler*.

*For Research Use Only.  Not for use in diagnostic procedures in the US.

Sponsored by
Sponsored by

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Sponsored by

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Sponsored by

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.